<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129301">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01733576</url>
  </required_header>
  <id_info>
    <org_study_id>CB64</org_study_id>
    <nct_id>NCT01733576</nct_id>
  </id_info>
  <brief_title>High-definition Transcranial Direct Current Stimulation (HD-tDCS) Verbal Learning</brief_title>
  <official_title>Enhancing Verbal Learning and Memory Using High-Definition Transcranial Direct Current Stimulation (HD-tDCS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of New South Wales</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of New South Wales</source>
  <oversight_info>
    <authority>Australia: Therapeutic Goods Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project will use a new form of non-invasive brain stimulation called high-definition
      transcranial direct current stimulation (HD-tDCS) to facilitate verbal learning. This form
      of stimulation is similar to transcranial direct current stimulation (tDCS) but allows for
      more spatially focused stimulation. We hypothesise that HD-tDCS when applied to regions of
      the brain important for learning and memory will improve verbal learning and memory compared
      to sham HD-tDCS.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 0</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Ray Auditory Verbal Learning Test (RAVLT)</measure>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Verbal Learning and Memory</condition>
  <arm_group>
    <arm_group_label>Sham HD-tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active HD-tDCS 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active HD-tDCS 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active HD-tDCS 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HD-tDCS</intervention_name>
    <arm_group_label>Sham HD-tDCS</arm_group_label>
    <arm_group_label>Active HD-tDCS 1</arm_group_label>
    <arm_group_label>Active HD-tDCS 2</arm_group_label>
    <arm_group_label>Active HD-tDCS 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 18 - 40 years

          -  Right-handed

        Exclusion Criteria:

          -  concurrent medication likely to affect mental performance

          -  current history of drug or alcohol abuse or dependence

          -  any psychiatric or neurological disorder, recent head injury, or history of  seizure
             or stroke.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Donel Martin, PhD</last_name>
    <phone>61 2 9382 9261</phone>
    <email>donel.martin@unsw.edu.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Black Dog Institute</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donel Martin, PhD</last_name>
      <phone>61 2 9382 9261</phone>
      <email>donel.martin@unsw.edu.au</email>
    </contact>
    <investigator>
      <last_name>Donel Martin, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>June 14, 2013</lastchanged_date>
  <firstreceived_date>November 26, 2012</firstreceived_date>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
